PATENT CLAIM ANALYSIS

Application Number: 15873810
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["607", "FOR000"]

Abstract:
A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.

Claim (Index 26):
The method of  claim 14 , the method further comprising introducing into the subject or into the sample one or more of the following: CD47-blocking antibodies, CTLA-4-blocking antibodies, PD-1-blocking antibodies, or doxorubicin.

Metadata:
- Claim Count in Document: 66.0
- Percentile: 86.0
- Lexical Diversity: 1.74699
- Patent Class: 607.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14287957', '14805828', '14954630', '15671014', '12280280']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6773600235961701
- 35 USC 102 Novelty (BERT): 0.615137644786772
- Combined Prediction Score: 0.6711377857152303
- Mean Citation Score: 448.34127
- Max Citation Score: 655.3408
- Similarity Product: 489.427379637146

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test